(037) CATCHING THE CURVE: LEVERAGING DISEASE PHASES FOR OPTIMAL COLLAGENASE THERAPY IN PEYRONIE’S PATIENTS

Abstract Introduction In the United States, collagenase clostridium histolyticum (CCH) injections are widely used as a treatment for patients with Peyronie’s disease (PD). While CCH is an approved treatment for PD, it is unclear from existing evidence if initiating this intervention during the acute phase vs the later chronic phase leads to different outcomes. Objective We sought to investigate the effectiveness and safety of CCH treatment in patients with PD, comparing outcomes between those in the active versus stable phase of the disease. Methods We performed an IRB-approved single-center retrospective study from 2009-2023 on patients with CCH injections for PD. Clinical and demographic information was extracted from patient medical records. Patients were stratified into two groups based on the phase of their disease at the time of treatment: active (acute) phase or stable (chronic) phase. Both groups were compared Pearson's Chi-square or Fisher's exact tests for categorical data. Results This study included 169 patients with a mean age of 57.9 (SD: 8.63). The patient cohort is summarized in Table 1. Of these, 144 and 25 patients received CCH in the chronic and acute phases, respectively. No significant difference was observed between the change in curvature of the active and stable phase (-7.4 [SD:14.73] vs. -7.82 [SD:16.04], p = 0.37, respectively). No significant difference was observed in curve improvement between the two phases (p = 0.864), indicating that treatment was equally effective in both phases. More patients in the stable phase had progression to surgery (p = 0.032). In terms of side effects, the incidences of bruising (p = 0.368), swelling (p = 0.811), pain (p = 0.846), hematoma (p = 0.479), and fracture (p = 0.457) did not differ significantly between the active and stable phases. The chi-square test results for new ED and loss of length should be interpreted cautiously due to small size cell counts. Conclusions These results suggest that CCH injection is a viable treatment option for PD patients in both the active and stable phases, with comparable efficacy in improving penile curvature deformity. Further prospective studies with larger sample sizes are warranted to validate these findings. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Disclosures: Consultant for AbbVie, Marius, Tolmar, Endo, Petros, Boston Scientific, Coloplast, Halozyme Investor: Sprout.